Defence of mucous membranes by antibodies, receptor analogues and non-specific host factors

Role of the mucosal barrier in toxin/microbial attachment to the gastrointestinal tract

An important component of bacterial infection of the gastrointestinal tract, particularly when enterotoxin disruption of gut function occurs, relates to the interaction of the bacterium and toxin with the intestinal surface. Adherence or attachment of bacteria lead to colonization and toxic/invasive diarrhoeal states. The purpose of this review is to consider the intestinal mucosal barrier as a deterrent to microbial/toxin attachment, particularly emphasizing the mucosal surface itself, which includes the mucus coat and microvillous membrane. Consequences of mucosal barrier deficiency, particularly the incomplete development of the mucosal barrier, result in bacterially induced diarrhoeal states such as toxigenic diarrhoea and necrotizing enterocolitis. To illustrate the importance of the mucosal barrier as a factor in controlling the external environment containing bacteria and bacterial toxins, recent research in our laboratory on the development of the mucosal barrier is presented. This compares mucosal surface functional control of antigen/toxin attachment and penetration with mucosal surface compositional changes. Finally, evidence of a preliminary nature will be provided to suggest that modifications of the underdeveloped mucosal barrier of the immature intestine by the ingestion of breast milk may act to prevent pathological interactions between the gut and microbes/toxins.

Expression of bovine lactoferrin and lactoferrin N-lobe by recombinant baculovirus and its antimicrobial activity against Prototheca zopfii

Lactoferrin (LF) is a multifunctional, iron-binding glycoprotein found in secretory fluids of mammals. In this study, DNA encoding bovine lactoferrin (bLF) or the N-terminal half of bLF (bLF N-lobe) was inserted into a baculovirus transfer vector, and a recombinant virus expressing bLF or bLF N-lobe was isolated. An 80-kDa bLF-related protein expressed by the recombinant baculovirus was detected by monoclonal antibodies against bLF N-lobe and the C-terminal half of bLF (bLF C-lobe). A 43-kDa bLF N-lobe-related protein expressed by the recombinant baculovirus was detected by anti-bLF N-lobe monoclonal antibody, but not by anti-bLF C-lobe monoclonal antibody. These proteins were also secreted into the supernatant of insect cell cultures. Recombinant bLF (rbLF) and bLF N-lobe (rbLF N-lobe) were affected by tunicamycin treatment, indicating that rbLF and rbLF N-lobe contain an N-linked glycosylation site. Antimicrobial activity of these recombinant proteins against Prototheca zopfii (a yeast-like fungus that causes bovine mastitis) was evaluated by measuring the optical density of the culture microplate. Prototheca zopfii was sensitive to rbLF and rbLF N-lobe, as well as native bLF. There was no difference in antimicrobial activity between rbLF N-lobe and bLF C-lobe.Key words: lactoferrin, lactoferrin N-lobe, baculovirus, antimicrobial activity, Prototheca zopfii.

Epithelial cytokine responses and mucosal cytokine networks

Localized at the border between the external environment and the internal tissue, epithelial cells are exposed to stimulants from two directions. Microorganisms in the lumen can activate the transcription of cytokine mRNA and cytokine secretion, and cytokines in the mucosal environment can modify endogenous and microbially induced epithelial cytokine responses. Epithelial cells thus actively participate in mucosal immunity and inflammation.

Inactivation of enveloped viruses in human bodily fluids by purified lipids

Antimicrobial lipids are found in mucosal secretions and are one of a number of nonimmunologic and nonspecific protective factors found at mucosal surfaces. Lipids can inactivate enveloped viruses, bacteria, fungi, and protozoa. Lipid-dependent antimicrobial activity at mucosal surfaces is due to certain monoglycerides and fatty acids that are released from triglycerides by lipolytic activity. Medium chain length antiviral lipids can be added to human blood products that contain HIV-1 and HIV-2 and reduce the cell-free virus concentration by as much as 11 log10 TCID50/ml. The presence of lipids does not interfere with most clinical assays performed on human blood samples. Antimicrobial lipids can disrupt cell membranes and therefore lyse leukocytes which potentially carry virus. Genital mucosal epithelial cells should be protected from damage by the mucous layer. Preliminary studies indicate that lipids decrease sperm motility and viability suggesting that lipids may potentially be used as combination spermicidal and virucidal agents.

Plasma lactoferrin content: differential effect of steroid administration and infective illnesses: lack of effect of ambient temperature at which specimens are collected

The effect of parenteral hydrocortisone on plasma lactoferrin concentration, neutrophil count and lactoferrin:neutrophil ratio was assessed in 10 volunteer subjects. Administration of a single dose of corticosteroid was followed by a significant rise in the circulating neutrophil count, a significant but proportionately smaller rise in the plasma lactoferrin concentration and a significant fall in the lactoferrin:neutrophil ratio. Acute viral infections were found to be associated with a disproportionately low plasma lactoferrin concentration relative to the circulating neutrophil count. The relatively low lactoferrin concentrations in both these situations could be of significance in regard to the propensity to bacterial infection and superinfection which these 2 groups of subjects display. Compared to patients with viral infection, those suffering from Plasmodium falciparum malaria showed a significantly elevated lactoferrin:neutrophil ratio, although this ratio was not significantly different when malarial patients were compared to normal individuals. These findings suggest that the pathogenesis of relative neutropenia in viral and protozoal illnesses is fundamentally different. Finally, it was found that the temperature at which specimen collection takes place does not appear to be a significant variable determining the plasma lactoferrin concentration.

Relationship of plasma lactoferrin content to neutrophil regeneration and bone marrow infusion

Plasma concentrations of lactoferrin were measured in immediately separated EDTA samples from 5 subjects who had received HLA identical bone marrow transplants for leukaemia or aplastic anaemia and from 7 subjects who were leukopenic as a consequence of chemotherapy for a variety of malignant conditions. Plasma lactoferrin concentrations were found to closely parallel the leucocyte count and were not found to either predict or to antedate leucocyte regeneration. Serial measurements of plasma lactoferrin in a subject with no circulating neutrophils who received a bone marrow graft revealed that the clearance of lactoferrin followed an exponential pattern and had an initial half time of 2.2 h.

Lack of correlation between iron stores and plasma lactoferrin concentration

Plasma lactoferrin concentration and indices of iron nutrition including P-Ferritin, P-iron, total iron binding capacity and percentage saturation were measured in 75 otherwise normal females. This was done in order to evaluate previous reports that neutrophil lactoferrin content was altered by variations in iron storage status. Since P-Lactoferrin is derived from and hence reflects neutrophil lactoferrin content it would seem reasonable to assume that P-Lactoferrin would vary in accordance with iron stores. However, there was no statistically significant difference in P-Lactoferrin concentration between iron deficient subjects and those who were iron replete. Furthermore, there was no statistically significant correlation between any iron related parameter and P-Lactoferrin concentration.